NCT00203957View on ClinicalTrials.gov

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Parkinson's Disease
Interventions
DRUG

Istradefylline

Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d

DRUG

Istradefylline

Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00203957 - Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa | Biotech Hunter | Biotech Hunter